Introduction {#s1}
============

Leishmaniases are caused by protozoa of the genus *Leishmania* and may present as a visceral or tegumentary disease. Typically found in tropical and subtropical areas, leishmaniases are endemic in 98 countries.[@R1] Visceral leishmaniasis (VL) is a systemic disease that affects the mononuclear phagocyte system,[@R2] whereas tegumentary leishmaniasis (TL) comprise localized cutaneous leishmaniasis (CL), leishmaniasis recidivans, disseminated cutaneous leishmaniasis (DL), diffuse CL (DCL), and mucosal leishmaniasis (ML); the specific manifestation is dependent on the *Leishmania* species and the host immune response.[@R3]

Diagnosis of leishmaniases is based on epidemiological data, clinical features, and laboratory test results, which include a parasitological examination and serological assays.[@R4] Parasitological examinations are accurate but laborious to perform, and they have low sensitivity.[@R5]--[@R8] However, when polymerase chain reactions (PCRs) are used for the search of *Leishmania* DNA, the sensitivity of the detection is considered higher. The sensitivity is even higher if the target gene is a kinetoplast DNA sequence that is present in multiple copies in *Leishmania*. Nevertheless, PCRs are not routinely used because of their technical complexity.[@R4],[@R5] Thus, assays commonly used in the serological diagnosis of VL are the indirect immunofluorescence assay (IIFA), the enzyme-linked immunosorbent assay (ELISA), and the direct agglutination test (DAT) using total *Leishmania* promastigote antigen.[@R3],[@R9],[@R10]

Serology is not a routine procedure for diagnosis of TLs, such as localized CL, because of the low sensitivity of the tests.[@R11],[@R12] In ML, serology may have a complementary role in diagnosis, because the sensitivity is higher.[@R13],[@R14] However, variable results have been achieved with serological methods; the sensitivity and specificity of such methods depend on the type, source, purity, and antigen preparation used.[@R12],[@R13],[@R15]--[@R17] In addition, *Leishmania* species-related variations in the results have been reported.[@R18]

One of the drawbacks in most currently available serological assays is that the antigen is either a total parasite lysate or whole promastigote, whose production depends on the intricate growth of the parasite. Development of recombinant *Leishmania* antigen for serological diagnosis would be valuable, because the production of such an antigen would be parasite growth-independent and more standardized and uniform. For VL, identification of the rK39 antigen has been a promising diagnostic contribution. It has been used in ELISA and immunochromatographic strip tests, which have facilitated field applicability,[@R10],[@R19] and they are now commonly used worldwide.[@R20]

Previously, *L. major* Hsp60[@R21] and *L. braziliensis* Hsp70[@R22] were cloned and tested in 15 CL samples from Colombia, which were found to have a mean optical density significantly higher than the optical density of sera from healthy negative controls. These two antigens were also tested in 46 ML samples from Brazil and had 89% sensitivity. More recently, Souza and others[@R23] evaluated seven *L. infantum*-derived recombinant proteins in 102 TL serum samples and found that Hsp70 was a promising antigen, with 65.0% sensitivity and 92.0% specificity. Previously, we had tested *L.* (*L.*) *infantum* Hsp83 using a limited number of CL and ML samples and obtained 100% reactivity.[@R24] Interestingly, we also found no cross-reactivity with Chagas disease serum samples.[@R24] Because the previous data showed good sensitivity and specificity in CL and ML, in this study, we investigated *L.* (*L.*) *infantum* Hsp83 in CL, ML, and VL samples to test its sensitivity as well as in samples from other infectious diseases (i.e., Chagas disease, blastomycosis, histoplasmosis, aspergillosis, chromomycosis, toxoplasmosis, cytomegalovirosis, malaria, and tuberculosis) to test for cross-reactivity.

In TL, anti-*Leishmania* antibodies level has been previously shown to drop after treatment, independent of cure or failure.[@R18] Therefore, we also performed serology on patient samples obtained during a follow-up visit to test anti-rHsp83 antigen antibody titers.

Similar to most of the currently available total parasite-based tests, the rHsp83 antigen test is not species-specific, and therefore, our test would be beneficial for leishmaniasis diagnostics.

Materials and Methods {#s2}
=====================

Antigens. {#s2a}
---------

*L. infantum* Hsp83 was expressed in *Escherichia coli* M15 as a recombinant protein and purified by Ni-NTA affinity chromatography (QIAGEN GmbH, Hilden, North Rhine-Westphalia, Germany).[@R25] The total *L. major*-like (MHOM/BR/71/49)[@R26] promastigote antigen was prepared according to the work by Hoshino-Shimizu and others,[@R27] with modifications.[@R28] The extract of this strain was used, because the reaction is genus-specific, and it can detect leishmaniasis caused by different species of *Leishmania*.[@R29],[@R30]

Patients and serum samples. {#s2b}
---------------------------

Sera from patients with CL (12) and ML (14) were obtained from patients treated at the Department of Dermatology, Faculdade de Medicina, Universidade de São Paulo. The clinical diagnosis was confirmed by parasitological and immunological methods. The lesions were examined for the presence of parasites directly and/or in biopsy specimens.[@R31] All patients except two had a positive intradermal Montenegro test.[@R32] The majority (86.6%) of patients was treated with pentavalent antimony (Sanofi Aventis Farmacêutica Ltda, Suzano, São Paulo, Brazil), 7.7% of patients were treated with Amphotericin B (Bristol-Myers-Squibb, São Paulo, São Paulo, Brazil), and 7.7% of patients received both treatments ([Table 1](#T1){ref-type="table"}). Sera from patients with VL (30) were from active VL patients in Piauí state, Northeastern Brazil, and patients had been diagnosed based on clinical presentation and positive serology and/or the presence of parasites in bone marrow. Sera from patients with other infectious diseases were collected from 79 patients: Chagas disease (*N* = 23), blastomycosis (*N* = 7), histoplasmosis (*N* = 6), aspergillosis (*N* = 5), chromomycosis (*N* = 7), toxoplasmosis (*N* = 14), cytomegalovirosis (*N* = 4), malaria (*N* = 9), and tuberculosis (*N* = 4). Samples from 30 healthy blood bank donors were used as controls.

Post-therapeutic evaluation of antibodies in CL and ML. {#s2c}
-------------------------------------------------------

For the serological follow-up, 12 patients with CL and 14 patients with ML were examined at three different time periods: at a baseline before the initiation of the therapy (T0) and 6 (T1), and 12 months (T2) after the onset of therapy. At T0, CL patients had a disease evolution time varying from 0.2 to 30 years (median = 0.45; interquartile 25--75% = 0.30--0.80), and ML patients had a disease evolution time ranging from 0.3 to 56 years (6.5; 1--40) ([Table 1](#T1){ref-type="table"}).

ELISA. {#s2d}
------

All sera were tested for immunoglobulin G (IgG) antibodies at 1:50 dilution in the ELISA using rHsp83 (ELISA-rHsp83) or whole *L. major*-like parasite lysate (ELISA--*L. major*-like) as previously described.[@R14],[@R24] For both antigens, the cutoff point was determined using a receiver operating characteristic (ROC) curve.[@R33] The reactivity index (RI) was calculated for each sample by dividing the sample absorbance value by the cutoff. Samples were considered positive if the RI value was ≥ 1.

Statistical analysis. {#s2e}
---------------------

The sensitivity and specificity of tests and the 95% confidence intervals (95% CIs) were calculated using the ROC curve. The results were compared using McNemar\'s test. The agreement between the ELISA results with rHsp83 or *L. major*-like antigen was estimated by the κ-index. Mann--Whitney rank sum test (two groups) and Friedman repeated measures analysis of variance on Ranks and Tukey test (three or more groups) were used to compare medians.

Ethical issues. {#s2f}
---------------

All participants gave informed consent individually before giving the blood samples. This study was approved by the Ethics Committees of the Instituto de Medicina Tropical de Sao Paulo, Universidade de São Paulo and the Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo.

Results {#s3}
=======

Performance of ELISA-rHsp83 compared with ELISA--*L. major*-like. {#s3a}
-----------------------------------------------------------------

The ROC curve was generated from 56 leishmaniasis patient samples and 30 healthy blood bank samples assayed by ELISA-rHsp83 ([Figure 1A](#F1){ref-type="fig"}) and ELISA--*L. major*-like ([Figure 1B](#F1){ref-type="fig"}). To reach a maximum specificity (95% CI) of 100.0% (88.43--100.0%), cutoff values were 0.070 for ELISA-rHsp83 and 0.190 for ELISA--*L. major*-like.

![ROC curve with leishmaniasis (*N* = 56) and control blood bank (*N* = 30) samples. (**A**) ELISA-rHsp83 generated a cutoff value of 0.070. (**B**) ELISA--*L. major*-like generated a cutoff value of 0.190.](tropmed-90-860-g001){#F1}

Using rHsp83 as the antigen in the ELISA assay led to a significantly higher sensitivity in detecting anti-*Leishmania* antibodies compared with using *L. major*-like antigen (*P* = 0.013, McNemar\'s test) ([Table 2](#T2){ref-type="table"}). Strong agreement between the evaluated antigens was observed, with κ = 0.807 (0.682--0.932). [Figure 2](#F2){ref-type="fig"} Figure 2.Reactivity index of sera from ML (*N* = 14), CL (*N* = 12), VL (*N* = 30), Chagas disease (CH; *N* = 23), other infectious diseases (OP; *N* = 56), and control blood bank donors (NC; *N* = 30) in (**A**) ELISA-rHsp83 and (**B**) ELISA--*L. major*-like. shows the reactivity of all tested serum samples with either antigen.

ELISA-rHsp83 and ELISA--*L. major*-like cross-reactivity to other infectious disease samples. {#s3b}
---------------------------------------------------------------------------------------------

We found an overall specificity (95% CI) of 97.47% (91.15--99.69%) and 70.89% (59.58--80.57%) for ELISA-rHsp83 and ELISA--*L. major*-like antigens ([Table 3](#T3){ref-type="table"}), respectively, in serum samples from patients with other infectious diseases. The difference in performance of the two antigens was significant (*P* \< 0.001, McNemar\'s test).

For samples from patients with Chagas disease, ELISA specificity was significantly higher with rHsp83 than *L. major*-like antigen (*P* \< 0.001, McNemar\'s test). In the sera from patients with other infectious disease (excluding Chagas disease), both antigens had the same specificity: 96.43% (95% CI = 87.69--99.56%; *P* = 0.617, McNemar\'s test). Non-specific reactions with rHsp83 antigen were observed with samples from aspergillosis and toxoplasmosis patients. With the *L. major*-like antigen, 21 of 23 (91.30%) serum samples from Chagas disease patients showed cross-reactivity ([Figure 3](#F3){ref-type="fig"}).

![(**A**) ELISA-rHsp83 and (**B**) ELISA--*L. major*-like cross-reactivity with other infectious disease samples: NC (*N* = 30), blastomycosis (Pb; *N* = 7), histoplasmosis (Hc; *N* = 6), aspergillosis (Af; *N* = 5), chromomycosis (Cr; *N* = 7), toxoplasmosis (toxo; *N* = 14), cytomegalovirosis (CMV; *N* = 4), CH (*N* = 23), malaria (Mal; *N* = 9), and tuberculosis (TB; *N* = 4).](tropmed-90-860-g003){#F3}

Post-therapeutic evaluation of anti-*Leishmania* antibody titers in ELISA-rHsp83 in CL and ML. {#s3c}
----------------------------------------------------------------------------------------------

We found no significant difference when assessing the post-therapeutic antibody levels in 26 patients with TL (CL = 12 and ML = 14) using ELISA-rHsp83 (Friedman repeated measures analysis of variance on ranks: ML \[*P* = 0.607\], CL \[*P* = 0.205\]). In contrast, ELISA--*L. major*-like median values showed a progressive decrease; the medians were significantly higher at T0 compared with T1 and T2 in ML (*P* = 0.0003) and at T0 compared with T2 in CL (*P* = 0.0023) ([Figure 4](#F4){ref-type="fig"}).

![Reactivity index for follow-up samples in ML and CL patients in (**A**) ELISA-rHsp83 and (**B**) ELISA--*L. major*-like. ^\$^*P* \< 0.05 compared with T0 in ML (Friedman repeated measures analysis of variance on ranks and Tukey test). ^\#^*P* \< 0.05 compared with T0 in CL (Friedman repeated measures analysis of variance on ranks and Tukey test).](tropmed-90-860-g004){#F4}

Discussion {#s4}
==========

Early diagnosis of leishmaniases is vital to avoid permanent damage, sequelae, and even death, depending on the disease form. Although detection of the parasite confirms diagnosis, the lack of detection does not exclude the presence of the disease or infection, because parasitological methods have low sensitivity.[@R3],[@R7],[@R31],[@R34]--[@R36]

In this study, we evaluated *L. infantum* rHsp83 as an antigen in ELISA for the diagnosis of CL, ML, and VL and compared the results with *L. major*-like total promastigote antigen. ELISA-rHsp83 was significantly more sensitive than ELISA--*L. major*-like when comparing results from all leishmaniasis patients (*P* = 0.013) and TL (*P* = 0.041). Previously, Guimarães and others[@R16] used ELISA--*L. major*-like and reported low sensitivity (66.3%) and specificity (77.5%) for TL patients, whereas Barroso-Freitas and others[@R13] obtained better results using ELISA-*L. braziliensis* (97.5% sensitivity and 100.0% specificity) for TL patients. Using seven *L. infantum*-derived recombinant proteins to test TL sera, Hsp70 was considered the most promising, with 65.0% sensitivity and 92.0% specificity.[@R23]

For VL patients, several groups have tested ELISA-*L. infantum* rK39 and found sensitivity/specificity values of 88.6%/92.4%[@R37] and 100%/96%.[@R38] ELISA-rK39 has high diagnostic and prognostic use in human immunodeficiency virus (HIV)-infected patients coinfected with *L. infantum*.[@R39] Reactivity of the widely used immunochromatographic test using the rK39 antigen was shown to vary depending not only on the patients\' origins but also, the product source.[@R20]

Although rK39 has been important for VL diagnosis, this antigen does not allow detection of antibodies in CL or ML.[@R40] However, the recombinant Hsp83 antigen detects VL, CL, and ML with high sensitivity (100.0%), a great advantage over the previously mentioned antigens.

Cross-reactivity of *Leishmania* antigens with sera samples from geographic areas where other protozoa diseases, particularly Chagas disease, overlap with leishmaniasis is common. Total promastigote antigen is known to cross-react with sera positive for several other infectious diseases, especially Chagas disease.[@R24],[@R30],[@R39] To overcome such non-specific reactions, several recombinant proteins have been tried with varying success. In this study, we obtained maximum indices with both ELISA-rHsp83 and ELISA--*L. major*-like for healthy blood bank samples. However, for serum samples from patients with other infectious diseases, rHsp83 was significantly more specific, particularly with respect to Chagas disease samples (*P* \< 0.001). Souza and others[@R23] obtained 90% specificity with rHsp70, whereas we found 100.0% specificity with rHsp83 in the Chagas disease samples. Aspergillosis and toxoplasmosis serum samples provided non-specific reactions with rHsp83, but the values were near the cutoff level and had lower positivity than has been observed in other studies.[@R31],[@R41]

In the present study, a significant decrease in antibody levels detected by ELISA--*L. major*-like was observed 6 months after the onset of therapy in ML patients and 12 months after therapy onset in CL patients, independent of the therapeutic response. Using ELISA-*L. amazonensis*, Romero and others[@R18] also observed a decrease in antibody levels in CL patients after treatment that was unrelated to therapeutic responses. In contrast, we did not detect a significant decrease in antibody levels post-treatment as measured by the ELISA-rHsp83. Control of cure by serological tests is a controversial subject in the literature.[@R42] The persistence of antibodies after treatment could indicate the continued presence of viable parasites, raising the possibility of a relapse.[@R43]

We believe that *L. infantum*-rHsp83 is a good antigen for use in the serodiagnosis of leishmaniases. Because of its high specificity and sensitivity and insignificant cross-reactivity with other infectious diseases, we suggest the ELISA-rHsp83 as a routine confirmatory serological assay for the diagnosis of *Leishmania* infection.
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###### 

Characteristics of 26 TL patients, including clinical form, duration of disease at baseline, number of relapses, and disease status

  Time    Relapses   Cured
  ------- ---------- ---------
  CL                 
   0.8    0          Yes
   0.4    1          Yes
   0.3    1          Yes
   0.5    2          Yes
   0.3    0          Yes
   0.2    1          Yes
   0.8    0          Yes
   0.3    0          Yes
   1.0    0          Yes
   0.3    1          Yes
   30.0   1          Yes
   0.6    0          Yes
  ML                 
   5.0    1          Unknown
   0.5    1          Yes
   0.7    1          Yes
   16.0   0          Yes
   0.3    0          Yes
   53.0   0          Yes
   50.0   1          Unknown
   20.0   1          Yes
   8.0    1          Yes
   1.0    0          Yes
   4.0    1          Yes
   40.0   1          Yes
   56.0   1          Yes
   1.0    3          Yes

Relapses = number of relapses; time = disease duration at baseline in years; unknown = up to the collection of the third sample, there was no report of the patient being cured; yes = patient was reported as cured before collection of the third sample.

###### 

Sensitivity and specificity of ELISA-rHsp83 and ELISA--*L. major*-like

  Samples          *N*   ELISA-rHsp83                            ELISA--*L. major*-like                     
  ---------------- ----- --------------------------------------- ------------------------ ----------------- --------------
  CL               12    100.0                                   73.54--100.0             83.33             51.59--97.91
  ML               14    100.0                                   76.84--100.0             71.43             41.90--91.61
  VL               30    100.0                                   88.43--100.0             93.33             77.93--99.18
  Total            56    100.0[\*](#TFN2){ref-type="table-fn"}   93.62--100.0             87.50             75.93--94.82
                         Sensitivity (%)                         CI (%)                   Sensitivity (%)   CI (%)
  Normal control   30    100.0                                   88.43--100.0             100.0             88.43--100.0

*P* = 0.013 compared with ELISA--*L. major*-like (McNemar\'s test).

###### 

Specificity (%) of ELISA-rHsp83 and ELISA--*L. major*-like for other infectious disease samples

  Samples             *N*   ELISA-rHsp83                            ELISA--*L. major*-like           
  ------------------- ----- --------------------------------------- ------------------------ ------- --------------
  Chagas disease      23    100.0[\*](#TFN3){ref-type="table-fn"}   85.18--100.0             8.70    1.07--28.04
  Blastomycosis       7     100.0                                   59.04--100.0             85.71   42.13--99.64
  Histoplasmosis      6     100.0                                   54.07--100.0             83.33   35.88--99.58
  Aspergillosis       5     80.00                                   28.36--99.49             100.0   47.82--100.0
  Cromomycosis        7     100.0                                   59.04--100.0             100.0   59.04--100.0
  Toxoplasmosis       14    92.86                                   66.13--99.82             100.0   76.84--100.0
  Cytomegalovirosis   4     100.0                                   39.76--100.0             100.0   39.76--100.0
  Malaria             9     100.0                                   66.37--100.0             100.0   67.37--100.0
  Tuberculosis        4     100.0                                   39.76--100.0             100.0   39.76--100.0
  Total               79    97.47[\*](#TFN3){ref-type="table-fn"}   74.97--91.90             70.89   58.25--79.47

*P* \< 0.001 compared with ELISA--*L. major*-like (McNemar\'s test).
